Spero Therapeutics (SPRO)
(Delayed Data from NSDQ)
$2.12 USD
-0.14 (-6.19%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $2.12 0.00 (0.00%) 7:44 PM ET
3-Hold of 5 3
F Value B Growth B Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
SPRO 2.12 -0.14(-6.19%)
Will SPRO be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SPRO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SPRO
Bayer Begins Phase I/II Study on Cell Therapy for Eye Disease
AZN's Imfinzi Wins EU Nod for Muscle-Invasive Bladder Cancer
SPRO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Vertex Gets EU Nod for New Cystic Fibrosis Drug Alyftrek
RCKT's IND for RP-A701 in Dilated Cardiomyopathy Gets FDA Clearance
ABBV to Boost Immunology Pipeline With Capstan Buyout for $2.1B
Other News for SPRO
Rare Stock Picks In June 2025 - From 26 Discerning Analysts
Spero Therapeutics Increases Stock Incentive Plan Shares
Spero Therapeutics -- Additional Upside Potential Following Positive Phase 3 Results
TD Cowen Remains a Hold on Spero Therapeutics (SPRO)
Largest borrow rate increases among liquid names